Evidence map›Paper›PMID 40087147›Full record

ReviewImmunotherapy2025

Effect of

Afroditi Ziogou, Alexios Giannakodimos, Ilias Giannakodimos, Dimitrios Schizas, Nikolaos Charalampakis

Abstract readReview
In one paragraph

Review in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Afroditi ZiogouDepartment of Medical Oncology, Metaxa Cancer Hospital of Piraeus, Piraeus, Greece.
Alexios GiannakodimosDepartment of Medical Oncology, Metaxa Cancer Hospital of Piraeus, Piraeus, Greece.
Ilias GiannakodimosDepartement of Urology, Attikon University Hospital of Athens, Athens, Greece.
Dimitrios SchizasFirst Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Nikolaos CharalampakisDepartment of Medical Oncology, Metaxa Cancer Hospital of Piraeus, Piraeus, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy for gastrointestinal cancers has elicited considerable amount of attention as a viable therapeutic option for several cancer types. Gut microbiome as a whole plays a critical role in shaping immune responses and influencing cancer progression. Recent evidence suggests that

Indexed as

Gastrointestinal NeoplasmsHelicobacter InfectionsHelicobacter pyloriImmunotherapyAnimalsGastrointestinal MicrobiomeHumansTumor Microenvironmentantibody therapeuticscancer immunologycancer vaccinescheckpoint inhibitorsGastrointestinal cancerHelicobacter Pyloriimmunotherapy

Identifiers

PMID40087147
PMCPMC12045566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.